S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   354.00 (-0.06%)
AAPL   170.48 (-0.86%)
MSFT   313.04 (+0.29%)
META   294.65 (-1.44%)
GOOGL   130.31 (+1.35%)
AMZN   126.14 (+0.13%)
TSLA   239.97 (-1.70%)
NVDA   424.19 (+1.21%)
NIO   8.49 (+0.95%)
BABA   86.02 (+0.13%)
AMD   98.37 (+2.51%)
T   14.89 (-0.87%)
F   12.38 (-0.40%)
MU   67.93 (-0.01%)
CGC   0.91 (-1.33%)
GE   111.03 (+1.00%)
DIS   79.84 (-0.26%)
AMC   7.62 (-3.67%)
PFE   32.24 (-0.49%)
PYPL   57.37 (-2.65%)
NFLX   379.29 (+0.01%)
S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   354.00 (-0.06%)
AAPL   170.48 (-0.86%)
MSFT   313.04 (+0.29%)
META   294.65 (-1.44%)
GOOGL   130.31 (+1.35%)
AMZN   126.14 (+0.13%)
TSLA   239.97 (-1.70%)
NVDA   424.19 (+1.21%)
NIO   8.49 (+0.95%)
BABA   86.02 (+0.13%)
AMD   98.37 (+2.51%)
T   14.89 (-0.87%)
F   12.38 (-0.40%)
MU   67.93 (-0.01%)
CGC   0.91 (-1.33%)
GE   111.03 (+1.00%)
DIS   79.84 (-0.26%)
AMC   7.62 (-3.67%)
PFE   32.24 (-0.49%)
PYPL   57.37 (-2.65%)
NFLX   379.29 (+0.01%)
S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   354.00 (-0.06%)
AAPL   170.48 (-0.86%)
MSFT   313.04 (+0.29%)
META   294.65 (-1.44%)
GOOGL   130.31 (+1.35%)
AMZN   126.14 (+0.13%)
TSLA   239.97 (-1.70%)
NVDA   424.19 (+1.21%)
NIO   8.49 (+0.95%)
BABA   86.02 (+0.13%)
AMD   98.37 (+2.51%)
T   14.89 (-0.87%)
F   12.38 (-0.40%)
MU   67.93 (-0.01%)
CGC   0.91 (-1.33%)
GE   111.03 (+1.00%)
DIS   79.84 (-0.26%)
AMC   7.62 (-3.67%)
PFE   32.24 (-0.49%)
PYPL   57.37 (-2.65%)
NFLX   379.29 (+0.01%)
S&P 500   4,274.99 (+0.03%)
DOW   33,565.28 (-0.16%)
QQQ   354.00 (-0.06%)
AAPL   170.48 (-0.86%)
MSFT   313.04 (+0.29%)
META   294.65 (-1.44%)
GOOGL   130.31 (+1.35%)
AMZN   126.14 (+0.13%)
TSLA   239.97 (-1.70%)
NVDA   424.19 (+1.21%)
NIO   8.49 (+0.95%)
BABA   86.02 (+0.13%)
AMD   98.37 (+2.51%)
T   14.89 (-0.87%)
F   12.38 (-0.40%)
MU   67.93 (-0.01%)
CGC   0.91 (-1.33%)
GE   111.03 (+1.00%)
DIS   79.84 (-0.26%)
AMC   7.62 (-3.67%)
PFE   32.24 (-0.49%)
PYPL   57.37 (-2.65%)
NFLX   379.29 (+0.01%)

Fate Therapeutics (FATE) Stock Forecast, Price & News

$2.11
+0.09 (+4.46%)
(As of 02:45 PM ET)
Compare
Today's Range
$2.00
$2.13
50-Day Range
$2.02
$4.60
52-Week Range
$1.99
$23.96
Volume
872,982 shs
Average Volume
2.89 million shs
Market Capitalization
$207.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.96

Fate Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.15 Rating Score
Upside/​Downside
523.2% Upside
$12.96 Price Target
Short Interest
Bearish
26.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
1.25mentions of Fate Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$59,353 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.91) to ($2.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

523rd out of 963 stocks

Biological Products, Except Diagnostic Industry

82nd out of 159 stocks


FATE stock logo

About Fate Therapeutics (NASDAQ:FATE) Stock

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

FATE Price History

FATE Stock News Headlines

U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Fate Therapeutics: Not Now, Maybe Never?
The Latest Analyst Ratings for Fate Therapeutics
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss
See More Headlines
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Company Calendar

Last Earnings
8/08/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
551
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.96
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+529.2%
Consensus Rating
Hold
Rating Score (0-4)
2.15
Research Coverage
20 Analysts

Profitability

Net Income
$-281,720,000.00
Net Margins
-177.41%
Pretax Margin
-177.41%

Debt

Sales & Book Value

Annual Sales
$96.30 million
Book Value
$4.98 per share

Miscellaneous

Free Float
93,594,000
Market Cap
$203.03 million
Optionable
Optionable
Beta
1.47
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. J. Scott WolchkoMr. J. Scott Wolchko (Age 53)
    Founder, CEO, Pres & Director
    Comp: $645k
  • Mr. Edward J. Dulac IIIMr. Edward J. Dulac III (Age 47)
    Chief Financial Officer
    Comp: $455k
  • Ms. Cindy R. TahlMs. Cindy R. Tahl (Age 50)
    Gen. Counsel & Corp. Sec.
    Comp: $455k
  • Dr. Bahram Valamehr Ph.D. (Age 46)
    Chief R&D Officer
    Comp: $455k
  • Mr. Jim Beitel M.B.A.
    Sr. VP of Corp. Devel.
  • Dr. Jerome Bressi Ph.D.
    Sr. VP of Regulatory & Quality













FATE Stock - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last twelve months. There are currently 2 sell ratings, 13 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price forecast for 2023?

20 brokers have issued 1 year price targets for Fate Therapeutics' shares. Their FATE share price forecasts range from $5.00 to $65.00. On average, they expect the company's share price to reach $12.96 in the next year. This suggests a possible upside of 529.2% from the stock's current price.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How have FATE shares performed in 2023?

Fate Therapeutics' stock was trading at $10.09 at the start of the year. Since then, FATE stock has decreased by 79.6% and is now trading at $2.06.
View the best growth stocks for 2023 here
.

Are investors shorting Fate Therapeutics?

Fate Therapeutics saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 24,290,000 shares, a decline of 12.1% from the August 31st total of 27,640,000 shares. Based on an average trading volume of 2,280,000 shares, the short-interest ratio is presently 10.7 days. Approximately 26.2% of the company's stock are short sold.
View Fate Therapeutics' Short Interest
.

When is Fate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our FATE earnings forecast
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) released its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($0.54) earnings per share for the quarter, beating analysts' consensus estimates of ($0.58) by $0.04. The biopharmaceutical company had revenue of $0.93 million for the quarter, compared to the consensus estimate of $5.41 million. Fate Therapeutics had a negative net margin of 177.41% and a negative trailing twelve-month return on equity of 44.14%. The business's revenue for the quarter was down 95.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.79) EPS.

What ETF holds Fate Therapeutics' stock ?

iShares Genomics Immunology and Healthcare ETF holds 348,530 shares of FATE stock, representing 0.86% of its portfolio.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?
What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.15%), State Street Corp (10.46%), JPMorgan Chase & Co. (2.77%), Geode Capital Management LLC (1.77%), Northern Trust Corp (1.27%) and Goldman Sachs Group Inc. (1.10%). Insiders that own company stock include Bahram Valamehr, Brian T Powl, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal, Yuan Xu and Yu-Waye Chu.
View institutional ownership trends
.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $2.06.

How much money does Fate Therapeutics make?

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $203.03 million and generates $96.30 million in revenue each year. The biopharmaceutical company earns $-281,720,000.00 in net income (profit) each year or ($2.17) on an earnings per share basis.

How many employees does Fate Therapeutics have?

The company employs 551 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.

This page (NASDAQ:FATE) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -